Ruzicka Daniel J, Imai Kentaro, Takahashi Kenichi, Naito Toshio
MSD K.K., Kitanomaru Square, 1-13-12 Kudan-kita, Chiyoda-ku, Tokyo, Japan.
Merck & Co., Inc., 2000 Galloping Hill Rd, Kenilworth, NJ, USA.
J Infect Chemother. 2019 Feb;25(2):89-95. doi: 10.1016/j.jiac.2018.10.006. Epub 2018 Nov 3.
This study examined the prevalence of chronic comorbidities and the use of co-medications among people living with HIV (PLWH) on antiretrovirals in Japan, compared with age-matched controls without HIV.
This was an observational, retrospective, cross-sectional study using a hospital claims database of Japanese hospitals with advanced medical capabilities (i.e., advanced treatment hospitals, general hospitals, acute care hospitals). We extracted data for PLWH aged ≥18 years with a prescription record of antiretrovirals between January 2010 and December 2015, and for age-, sex-, and hospital-matched people without HIV. For each group, chronic comorbidities (diabetes, hypertension, lipid disorders, vascular diseases, chronic kidney failure, cancers, psychiatric disorders, osteoporosis, and hepatitis B/C co-infection), and co-medications were examined by age group.
We analyzed data for 1445 PLWH and 14,450 people without HIV. The proportion of patients with multiple comorbidities was much greater among PLWH than controls of the same age group. Lipid disorders and diabetes were more prevalent in PLWH than controls (31.6% vs. 10.3% and 26.8% vs. 13.2%, respectively), both of which were more common in PLWH at earlier ages. Cancer was present in 8.1% of PLWH and 8.9% of controls. A greater proportion of PLWH used multiple co-medications other than antiretrovirals at earlier ages than controls.
PLWH taking antiretrovirals in Japan had a greater burden of comorbidities and co-medications with increasing age than people without HIV. In addition to appropriate management of comorbidities, medication reconciliation according to patients' co-medication profiles is important for successful management of this patient population.
本研究调查了日本接受抗逆转录病毒治疗的艾滋病病毒感染者(PLWH)中慢性合并症的患病率以及联合用药情况,并与年龄匹配的未感染艾滋病病毒的对照组进行比较。
这是一项观察性、回顾性横断面研究,使用了具有先进医疗能力的日本医院(即高级治疗医院、综合医院、急症医院)的住院理赔数据库。我们提取了2010年1月至2015年12月期间年龄≥18岁且有抗逆转录病毒药物处方记录的PLWH的数据,以及年龄、性别和医院匹配的未感染艾滋病病毒的人群的数据。对于每组,按年龄组检查慢性合并症(糖尿病、高血压、血脂异常、血管疾病、慢性肾衰竭、癌症、精神障碍、骨质疏松症和乙型/丙型肝炎合并感染)和联合用药情况。
我们分析了1445例PLWH和14450例未感染艾滋病病毒的人群的数据。PLWH中患有多种合并症的患者比例比同年龄组的对照组高得多。PLWH中血脂异常和糖尿病的患病率高于对照组(分别为31.6%对10.3%和26.8%对13.2%),这两种疾病在较年轻的PLWH中更为常见。8.1%的PLWH和8.9%的对照组患有癌症。与对照组相比,更大比例的PLWH在较年轻时使用了除抗逆转录病毒药物之外的多种联合用药。
在日本,接受抗逆转录病毒治疗的PLWH随着年龄增长,合并症和联合用药的负担比未感染艾滋病病毒的人更大。除了对合并症进行适当管理外,根据患者的联合用药情况进行用药核对对于成功管理这一患者群体很重要。